刚刚，直线拉升！美国，传来大消息！

Core Viewpoint - The recent approval of the revised Biological Safety Act as part of the 2026 National Defense Authorization Act (NDAA) in the U.S. is expected to positively impact the innovative drug sector, leading to a recovery in the industry and a return to long-term growth logic [2][4]. Group 1: Market Performance - A-shares and Hong Kong stocks in the innovative drug sector have seen significant gains, with companies like Huaren Health and Seli Medical hitting the daily limit up of 20% [1]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced a net inflow of funds for seven consecutive days, with the latest fund size reaching 4.172 billion shares, a record high since its listing [1]. Group 2: Legislative Impact - The revised Biological Safety Act was passed with a vote of 77 to 20 and will be sent to the White House for presidential approval, which will make it effective immediately [2]. - The act does not specifically name any companies but mandates the Office of Management and Budget (OMB) to create a list of restricted companies within a year, based on input from the Department of Defense [2]. Group 3: Industry Outlook - Analysts believe that the passage of the 2025 NDAA marks a phase of stabilization for the industry, allowing for a focus on long-term growth opportunities [2]. - The CXO (Contract Research Organization) sector is showing improved valuation and is expected to experience upward trends in 2026, with leading companies maintaining competitive advantages [3][4]. Group 4: Economic Environment - External factors affecting the CXO industry, such as the U.S. Biological Safety Act and drug tariffs, are showing signs of marginal improvement, leading to a more favorable sentiment in the market [4]. - The industry is entering a new high prosperity cycle driven by overseas interest rate cuts, domestic recovery, and industrial upgrades [4]. Group 5: Collaboration and Innovation - Recent collaborations, such as the agreement between Senrida Medical and Boston Scientific, indicate increased attention from global pharmaceutical companies towards innovative medical devices in China [5]. - The medical device sector is positioned to benefit from advancements in medical information technology and AI applications, enhancing productivity [5].